argenx SE (NASDAQ:ARGX) Shares Bought by Sei Investments Co.

Sei Investments Co. lifted its position in shares of argenx SE (NASDAQ:ARGX) by 15.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 381,544 shares of the company’s stock after purchasing an additional 50,477 shares during the period. Sei Investments Co. owned about 0.64% of argenx worth $164,079,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in argenx by 49.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after buying an additional 1,830,651 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after acquiring an additional 346,178 shares during the period. Janus Henderson Group PLC raised its position in argenx by 24.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after purchasing an additional 439,889 shares during the last quarter. Capital World Investors boosted its stake in argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock worth $746,099,000 after purchasing an additional 530,181 shares during the period. Finally, Avoro Capital Advisors LLC grew its position in argenx by 0.3% during the 1st quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after purchasing an additional 3,900 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $533.00 on Friday. argenx SE has a 12 month low of $327.73 and a 12 month high of $554.74. The firm has a market capitalization of $31.68 billion, a price-to-earnings ratio of -94.17 and a beta of 0.62. The business’s 50 day simple moving average is $512.59 and its 200-day simple moving average is $432.45.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The company had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same period in the previous year, the business earned ($1.69) earnings per share. On average, equities analysts anticipate that argenx SE will post -0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of research reports. Barclays raised shares of argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Stifel Nicolaus increased their price objective on argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. William Blair reiterated a “market perform” rating on shares of argenx in a research note on Monday, June 17th. Truist Financial upped their price target on argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Finally, Evercore ISI lifted their price objective on shares of argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $547.74.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.